Company Named After Medieval German Hero Wants Drug Import License
Published Date: 11/26/2025
Notice
Summary
Siegfried Grafton, Inc. wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Schedule I Substances
Siegfried Grafton, Inc. applied on September 1, 2025 to be a federal importer for the Schedule I substances gamma hydroxybutyric acid (GHB), marihuana extract, marihuana, MDMA (3,4-methylenedioxymethamphetamine), and dimethyltryptamine (DMT). If registered, the company would be authorized to import those substances only for analytical testing or distribution. Interested parties may submit comments or request a hearing by December 26, 2025.
Import Restriction: No Finished Dosage Forms
The DEA notice states that any importer registration will not authorize the import of Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale. That means import permission would be limited to non-finished forms (e.g., bulk material) and not permit bringing finished commercial drug products into the U.S.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in